Trial 3C-22-2


A Phase 2, Randomized, Open-Label Study of Encorafenib and Cetuximab Plus Pembrolizumab Versus Pembrolizumab Alone In Participants with Previously Untreated BRAF V600e-Mutant, MSI-H/DMMR Metastatic Colorectal Cancer (SEAMARK)

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Chemotherapy: Local, Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Charlean Ketchens, R.N., Jiayi Jiang, D.M., Noureddine Miloud, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator, Young-Wook Kim, Coordinator, Syed Husein, D.M., Diane Chun, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.